OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-18

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

While there are indications that 28 days of miltefosine is not sufficient for treating CL by L. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking. In this study, longitudinal measurements of parasite and drug concentrations during treatment are done to monitor parasite kinetics as well as pharmacokinetics. This data will be crucial to provide more information on duration and dosing of miltefosine in CL patients globally, and in Ethiopia and pediatric patients in particular.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcomes of Complicated CL in Ethiopia Treated With Miltefosine

NCT04004754

Cutaneous Leishmaniases

COMPLETED

Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan

NCT04268524

Old World Cutaneous Leishmaniasis

RECRUITING PHASE3

Miltefosine for Mucosal Leishmaniasis

NCT00373776

Leishmaniasis

COMPLETED PHASE1/PHASE2

Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨

NCT02687971

Cutaneous Leishmaniasis

COMPLETED PHASE2

Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia

NCT05332093

Cutaneous Leishmaniases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this project, parasite dynamics and miltefosine pharmacokinetics in the skin and blood during routine durations of miltefosine treatment (4-8 weeks) are studied with the aim to provide evidence to optimize miltefosine dosing for treatment of CL. By also studying these factors in children who get allometric miltefosine dosing, data which can be used to adapt the current allometric dosing scheme specifically to children with CL will be produced. Exploratory objectives will look into searching for more objective outcome assessment measures, resistance, helminth infection and nutritional status as potential factors affecting treatment response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cutaneous Leishmaniases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-allometric dosing

40 patients who will not use allometric dosing will be included

miltefosine will be given based on weight: 30-45 kg: 100mg miltefosine per day \>45 kg: 150mg miltefosine per day

Miltefosine

Intervention Type DRUG

Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks

allometric dosing (weight below 30 kg)

40 patients who weigh less than 30kg and therefore get allometric dosing will be recruited.

Dosing is given based on weight, height, and sex, according to Dorlo et al 2012

Miltefosine

Intervention Type DRUG

Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Miltefosine

Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical or parasitological (microscopy or PCR) confirmation of leishmaniasis
* Age \>2
* Clinical decision to start miltefosine treatment as systemic treatment
* In case of females of child-bearing age: willing to take contraceptive for 6 months (parenteral or IUD or implant)
* Willing and able to provide informed consent
* Willing to be hospitalized for the duration of treatment

Exclusion Criteria

* Currently on treatment or having received modern treatment for leishmaniasis in the last 3 months
* Pregnant (pregnancy test at D0) or breastfeeding
* Unlikely to come for follow-up visits
* Abnormal lab values Hemoglobin \<5.0g/100mL Platelets \<50 x 10\^9/L White blood count \<1 x 10\^9/L ASAT/ALAT \>3x upper normal range Creatinine above the normal limit

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No